Immuneering announces updated data from Phase 2a trial for atebimetinib

Immuneering (IMRX) Corporation announced that updated data from the Phase 2a clinical trial evaluating atebimetinib, IMM-1-104, in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients will be presented as an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL. The oral presentation will highlight data from an expanded cohort totaling 55 first-line patients, which includes the initial cohort of 34 patients that the company previously reported plus an additional 21 patients. “We are excited to present new survival data from an expanded cohort of 55 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in an oral presentation at ASCO,” said Ben Zeskind, Ph.D., CEO of Immuneering. “Atebimetinib was designed with three distinct mechanisms to promote survival: shrinking tumors durably, preserving body mass, and maximizing tolerability.”